The Macula Society
Fluorescein Cases for 2006
Wednesday, February 22, 2006

Fluorescein Angiography/Retinal Case Conference

Session 1
4:00-5:10 p.m.

Chair: Lawrence A. Yannuzzi
Moderator: H. Richard McDonald

4:00 p.m. Allen, Arthur
Unknown

4:05 p.m. Barr, Charles
Unknown

4:10 p.m. Paul S. Bernstein
Tamoxifen retinopathy with bilateral macular holes

4:15 p.m. Herbert Cantrill
Choroidal mass lesion

4:20 p.m. Salomon Cohen
Unknown

4:25 p.m. Roberto Costa
Occult Chorio-Retinal Anastomosis in Non-AMD Patients

4:30 p.m. Paulus deJong
Mystery case

4:35 p.m. James Folk
Fulminant Neovascularization from Choroidal Scars in a Diabetic

4:40 p.m. Michaella Goldstein
Unusual case of radiation retinopathy

4:45 p.m. Justin Gottlieb
Choroiditis

4:50 p.m. Lee M. Jampol
Unknown

4:55 p.m. Leonard Joffe
Unknown

5:00 p.m. Gregg Kokame
Inner Lamellar Macular Hole

5:05 p.m. Anat Loewenstein
A growing "bieb"

5:10 p.m. Refreshment Break
The Macula Society
Fluorescein Cases for 2006
Wednesday, February 22, 2006

Fluorescein Angiography/Retinal Case Conference

Session 2
5:25-6:35 p.m.

Chair: Charles C. Barr

Moderator: Lee M. Jampol

5:25 p.m.  Travis Meredith
Melanocytic Lesion

5:30 p.m.  Martine Mauget-Fayssé
Photodynamic Therapy as a palliative treatment for choroidal metastasis from lung adenocarcinoma

5:35 p.m.  Michael Marmor
Do we really need the Fovea?

5:40 p.m.  Lawrence Morse
Retinal neovascularization in healthy man with unilateral posterior uveitis

5:45 p.m.  Timothy Olsen
Serous Detachment in SLE

5:50 p.m.  Ayala Pollack
Intravitreal Avastin

5:55 p.m.  Jose Pulido
Choroidal mass of unknown etiology

6:00 p.m.  Stephen Sinclair
Anterior ischemic optic neuropathy with CME after PPV following blunt trauma

6:05 p.m.  Jason Slakter
Mystery case

6:10 p.m.  Bernadette Snyers
Unknown

6:15 p.m.  Janet Sunness
Stargardt Dilemna

6:20 p.m.  Paul Tornambe
An intra-operative demonstration how air current forces from the infusion cannula may damage retinal or optic nerve tissue

6:25 p.m.  Lawrence A. Yannuzzi
Mystery case

6:30 p.m.  Shin Yoneya
Churg Strauss Syndrome

6:35 p.m.  End of Session
The Macula Society
29th Annual Meeting
Four Seasons Aviara, North San Diego, California
February 22-25, 2006

SCIENTIFIC PROGRAM

THURSDAY, FEBRUARY 23, 2006

Session I: Hereditary Diseases

Chair: Ed Stone
Moderator: Muna Naash

7:30 a.m. OCT and Multifocal ERG Findings in Three Generations of a Family with Best Disease
Robert N. Frank

7:39 a.m. The Importance of the Mutation Detection Probability Distribution and the Estimate of
Pathogenic Probability for Efficient Genetic Testing of Inherited Eye Disease
Edwin M. Stone

7:48 a.m. Non-Viral Gene Therapy for Macular Dystrophies Caused by Mutations in RDS
Muna Naash

7:57 a.m. Identification and Characterization of Novel Mutations and Mutation Hot-Spot in Patients with
Enhanced S Cone Syndrome
Kent Small

Session II: AMD Imaging

Chair: Karl Csaky
Moderator: Michael Ip

8:06 a.m. The Utility of Dynamic Indocyanine Green Angiography (D-ICG) in Patients with Neovascular
Age-Related Macular Degeneration (AMD) as Determined by Two Prospective Clinical Trials
Karl Csaky

8:15 a.m. Is There an Inherent Difference in Reading Center Angiographic Interpretations and Outcome
Results in Clinical Trials: Results of the V.I.S.I.O.N. Trials
Michael Ip

8:24 a.m. The Relationship Between Computer-Assisted Estimates and Physician Assessment of Changing
Lesion Size of Predominantly Classic Choroidal Neovascular Membranes in Age-Related
Macular Degeneration: Sensitivity, Clinical Significance, and Accuracy
Dennis P. Han

8:33 a.m. Reproducibility in Grading Fluorescein Angiograms of Patients with Neovascular AMD Among
Retina Specialists
Michaella Goldstein

8:42 a.m. Decreases in the Foveolar Choroidal Circulation Precede the Appearance of Choroidal
Neovascularization in Age-Related Macular Degeneration
Juan E. Grunwald
8:51 a.m.  Fluorescence- and Resonance Raman-Based Quantitative Imaging of Human Macular Pigment Distributions
Paul S. Bernstein

9:00 a.m.  Follow Up Results of PCV in Korea According to ICG Angiographic Morphologic Classification
Oh W. Kwon

9:09 a.m.  Indocyanine Green Angiography Features of Drusen in Young Adults
Eric H. Souied

9:18 a.m.  Refreshment Break

Session III:  AMD Progression

Chair: Susan Bressler  Moderator: Emily Chew

9:38 a.m.  The Effect of Cataract Surgery on the Development of Neovascular Age-Related Macular Degeneration (AMD)
Susan B. Bressler

9:47 a.m.  Comparison of Five-Year Rates of Late AMD in CAPT Untreated Eyes with Predictions from the AREDS Simple Severity Scale
Stuart L. Fine

9:56 a.m.  Progression of Age-Related Macular Degeneration in African-Americans Enrolled in the Age-Related Eye Disease (AREDS), Using the AREDS Simple Scale
Emily Y. Chew

10:05 a.m.  Designing Clinical Trials for Age-Related Geographic Atrophy of the Macula
Janet S. Sunness

10:14 a.m.  Progression of Visual Loss in Untreated Eyes with Subfoveal Exudation in AMD:  A Meta Analysis
Lucian V. Del Priore

Session IV:  AMD Genetics

Chair: Michael Klein  Moderator: James Folk

10:23 a.m.  Reticular Pseudodrusen:  Incidence in Newly Diagnosed CNV and Links to ARM/AMD
Salomon Y. Cohen

10:32 a.m.  An Epidemiologic Study of Age-Related Macular Degeneration (AMD) in Carriers of the Apolipoprotein A-1-Milano Mutation:  A Novel Treatment Approach to AMD
Jorge G. Arroyo

10:41 a.m.  Plasma Complement Level, Complement Factor H Polymorphism and Age-Related Macular Degeneration
Victor Chong
10:50 a.m.  Correlation Between Complement Factor H Polymorphism Y402H and AMD Phenotype
James C. Folk

10:59 a.m.  Complement Factor H Polymorphism, Inflammation, and Aging Macular Disease in the General Population
Paulus T.V.M. de Jong

11:08 a.m.  The CFH Susceptibility Allele in Extended Families and in a Sporadic Case-Control Population
Michael L. Klein

11:17 a.m.  Mutation Spectrum and Evidence of Reduced Fibulin 5 Secretion in Age-Related Macular Degeneration and Cutis Laxa
Andrew Lottery

Session V: Pharmaceuticals/Drug Delivery

Chair: Timothy Olsen  Moderator: Mandi Conway

11:26 a.m.  Carotenoid-Mediated Retinal Delivery of Triamcinolone and Ketorolac
Dennis M. Marcus

11:35 a.m.  Buffering Capacity of Bovine Vitreous
Mandi D. Conway

11:44 a.m.  The Risky Business of Off-Label Use of Prescription Drugs
Robert Braunstein

11:53 a.m.  Cannulation of the Suprachoroidal Space: A Novel Route for Drug Delivery to the Posterior Segment
Timothy W. Olsen

12:02 p.m.  Posterior Juxtascleral Infusion of a New Formulation of Triamcinolone Acetonide for the Treatment of Refractory Diabetic Macular Edema
Paolo Lanzetta

12:11 p.m.  Presentation of the Arnall Patz Medal
Recipient:  Michael L. Klein, MD
Presenter:  Daniel Finkelstein, MD

12:16 p.m.  Paul Henkind Memorial Lecture and Award Presentation
New Therapy for Diabetic Maculopathy Using the Selective Retinal Pigment Epithelium Nd:YLF Laser
Recipient:  Peter Hamilton, MD
Presenter:  Steven Schwartz, MD

12:36 p.m.  Helen Keller Foundation
Lawrence J. Singerman

12:46 p.m.  Session Ends
FRIDAY, FEBRUARY 24, 2006

Business Meeting

7:00 a.m.  Macula Society Members Only

Session VI: AMD Pharmacology, Part I

Chair: Richard Spaide  Moderator: H. Richard McDonald

7:30 a.m.  Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration (IbeNA Study): Results of a Single Treatment in a Phase 1 and 2 Study
           Rogerio A. Costa

7:39 a.m.  Intravitreal Avastin for Choroidal Neovascularization
           Robert N. Johnson

7:48 a.m.  Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
           Carmen A. Puliafito

7:57 a.m.  Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
           Richard F. Spaide

8:06 a.m.  Ranibizumab (Lucentis) Self-Reported Vision Specific Quality of Life through 12 months in Age-Related Macular Degeneration Patients with Minimally Classic or Occult with No Classic Choroidal Neovascularization in a Phase III Randomized Clinical Trial
           Tom S. Chang

8:15 a.m.  Ranibizumab for Neovascular Age-Related Macular Degeneration: 1-year Subanalysis Results of the Marina Study
           Allen Ho

8:24 a.m.  Anatomic Outcomes from the Marina Study of Ranibizumab (Lucentis) for Minimally Classic or Occult Neovascular Age-Related Macular Degeneration
           Gregg T. Kokame

8:33 a.m.  One-year Fluorescein Angiography and Optical Coherence Tomography Results of the ANCHOR Study Comparing Ranibizumab with Verteporfin Photodynamic Therapy in Predominantly Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
           Jennifer I. Lim

8:42 a.m.  One-Year Results of ANCHOR: A Phase III, Multicenter, Randomized, Double-Masked Comparison of Ranibizumab and Verteporfin Photodynamic Therapy in Treatment of Predominantly Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
           H. Richard McDonald
8:51 a.m.  Efficacy and Safety of Pegaptanib in Age-Related Macular Degeneration: Three-year Results of the V.I.S.I.O.N. Trials
Usha Chakravarthy

9:00 a.m.  Retinal Pigment Epithelial Tears Following Intravitreal Macugen Injection for Age-Related Macular Degeneration
Christina Flaxel

9:09 a.m.  Two-year Systemic Safety of Pegaptanib in Patients with Neovascular Age-Related Macular Degeneration: Results of the V.I.S.I.O.N. Trials
Lawrence J. Singerman, MD

9:18 a.m.  Severe Systemic Allergic Responses Associated with Vitreous Injections of Pegaptanib Sodium
Stephen R. Russell

9:27 a.m.  Richard and Hinda Rosenthal Foundation Lecture and Award Presentation
Title: Neovascular AMD in the Ranibizumab Era: What’s Next for 2006?
Recipient: Anat Loewenstein, MD
Presenter: Susan Bressler, MD

9:47 a.m.  Refreshment Break

Session VII: AMD Pharmacology, Part 2, Laser

Chair: Thomas Friberg  
Moderator: Jason Slakter

10:05 a.m.  Verteporfin Enhanced Feeder Vessel Therapy in Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
William R. Freeman

10:14 a.m.  PDT in Occult-only Lesions in (POOL): 12-Month Results of a Phase IV Open-Label Multicenter Study of Verteporfin Therapy for Occult with No Classic Subfoveal CNV Secondary to AMD
Daniel Pauleikhoff

10:23 a.m.  Effect on High Contrast Discriminated Target Central Fields of Photodynamic Therapy with Verteporphyrin for CNVM Due to AMD
Stephen H. Sinclair

10:32 a.m.  PDT and Intravitreal Triamcinolone for the Treatment of CNV-Results of a Large Case Series
Albert J. Augustin

10:41 a.m.  Prospective Evaluation of Triple Therapy of Triamcinolone Intravitreal+PDT and Pegaptanib Sodium Injection for ARMD
Peter Liggett

10:50 a.m.  Open-Label, Multicenter, Phase II Study Assessing the Effects of Ranibizumab (Lucentis) Administered in Conjunction with Verteporfin PDT
Ursula Schmidt-Erfurth

10:59 a.m.  Extended Benefit of Combined Treatment for Wet AMD
Bert M. Glaser
11:08 a.m. Results of the Bilateral Arm of the PTAMD (Prophylactic Treatment of AMD) Trial
Thomas R. Friberg

11:17 a.m. Treatment of Retinal Angiomatic Proliferation Lesions in the Inner Retina with Focal Pulsed Laser
Robert P. Murphy

11:26 a.m. Aneqortave Acetate Risk Reduction (AART) Study Clinical Update – Patient Demographics and Baseline Characteristics
Jason S. Slakter

11:35 a.m. Presentation of the J. Donald M. Gass Medal
Recipient: Emily Y. Chew, MD
Presenter: Frederick L. Ferris III, MD

Session VIII: Tumors

Chair: J. William Harbour
Moderator: Joan O’Brien

11:40 a.m. Neovascular Glaucoma Risk Factors and Outcome after Charged Particle Therapy of Uveal Melanoma
Devon H. Char

11:49 a.m. Molecular Predictive Testing Using Gene Expression Profiling of Fine Needle Biopsy Specimens in Uveal Melanoma
J. William Harbour

11:58 a.m. Long-Term Follow-Up of Patients in a Randomized Controlled Trial of 70 CGE Versus 50 CGE Proton Radiation for the Treatment of Ocular Melanoma
Evangelos S. Gragoudas

12:07 p.m. Treatment of Transgenic Murine Retinoblastoma with 4-IODO-3-Nitrobenzamide (INO2BA), A Novel Chemotherapeutic Agent
Joan M. O’Brien

12:16 p.m. End of Session

SATURDAY, FEBRUARY 25, 2006

Session IX: Non-Diabetic Retinal Vascular Diseases

Chair: Alain Gaudric
Moderator: Don D’Amico

7:30 a.m. Fundus Autofluorescence: Beyond AMD
Lawrence A. Yannuzzi

7:39 a.m. Optical Coherence Tomography in Group 2 Juxtafoveal Retinal Telangiectasis
Alain Gaudric

7:48 a.m. Lamina Puncture for Central Retinal Vein Occlusion
Donald J. D’Amico
7:57 a.m. Surgical Acceleration of Collateral Formation for Branch Retinal Vein Occlusion
Fumio Shiraga

Session X: Diabetes

Chair: Lloyd Aiello
Moderator: Julia Haller

8:06 a.m. Effect of the Orally-Administered PKC B Inhibitor, Ruboxistaurin, On Sustained Moderate
Visual Loss in the Phase 3 PKC-DRS2 Study
Lloyd P. Aiello

8:15 a.m. Initial Clinical Experience with a Patterned Scanning Laser (PASCAL) for the Treatment of
Retinal Diseases
Julia A. Haller

8:24 a.m. Nitrate and Amino Acid Levels in the Vitreous of Proliferative Diabetic Retinopathy
Jose S. Pulido

8:33 a.m. Results of the Phase 1 Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal
Injections of Ranibizumab in Subjects with Diabetic Macular Edema
Quan Dong Nguyen

8:42 a.m. Vitrectomy with Drainage of Chronic Diabetic Cystoid Macular Edema Unresponsive to Other
Treatments
Hilel Lewis

8:51 a.m. A Randomized Trial of Intravitreal Triamcinolone vs. Macular Laser Therapy for Persistent
Clinically Significant Diabetic Macular Edema
Phil Hykin

9:00 a.m. Changes in Optical Coherence Tomography (OCT) Following Pegaptanib (Magenta) Therapy in
Diabetic Individuals
Neil M. Bressler

9:09 a.m. A Relation Between Oxygen Saturation Levels in the Macula in Eyes with Diabetic Retinopathy
and Flame-Shaped Hemorrhages
Shin Yoneya

Session XI: Surgery

Chair: James Tiedeman
Moderator: Matthew Thomas

9:18 a.m. Combined Pars Plana Vitrectomy/Lensectomy as a Primary Procedure for Idio pathic Macular
Hole Repair Without Postoperative Prone Positioning
James S. Tiedeman

9:27 a.m. Arcuate Retinotomy for Repair of Very Large, Failed Macular Holes
Steve Charles
9:36 a.m.  Comparison of Submacular Surgery and Natural History in Eyes with Large Submacular Hemorrhages from Exudative Macular Degeneration  
John T. Thompson

9:45 a.m.  Vitreous Consumes Oxygen: Implications for Vitrectomy Surgery  
Nancy M. Holekamp

9:54 a.m.  Long Term Follow-up of Patients with Surgical Removal of Extensive Peripapillary Choroidal Neovascularization Associated with Presumed Ocular Histoplasmosis Syndrome  
Matthew A. Thomas

10:03 a.m.  Refreshment Break

Session XII: Basic Science

Chair: Anthony Adamis  
Moderator: Lawerence Morse

10:22 a.m.  The Role of VEGF in Retinal Inflammation and Neuroprotection  
Anthony P. Adamis

10:31 a.m.  Anti-Angiogenic Efficacy of the Novel Antioxidant, OT-674, in Inhibiting Oxidative Stress and Growth Factor-Mediated Angiogenesis  
Leonard M. Parver

10:40 a.m.  The Role of Cell-Associated VEGF in Endothelial Cell Transmigration Across the Retinal Pigment Epithelium  
Mary Elizabeth Hartnett

10:49 a.m.  Intravitreal Injection of Bone Marrow Derived Stem Cells after Laser Treatment to Central Retina  
Dov Weinberger

10:58 a.m.  Cholesterol Depletion Blocks Fas-Mediated Apoptosis and Membrane Raft Formation in Human RPE cells  
Lawrence Morse

11:07 a.m.  Pharmacological Manipulation of the Intracellular Fate of Misfolded P23H OPSIN  
Shalesh Kaushal

11:16 a.m.  Migration and Proliferation of Retinal Pigment Epithelium on Extracellular Matrix Ligands  
Marco Zarbin

11:25 a.m.  W. Richard Green Lecture and Presentation of Award  
A reappraisal of retinal photocoagulation treatment parameters: the impact of power and duration on size and character of the burn  
Recipient: Mark Blumenkranz, MD  
Presenter: Lawrence J. Singerman, MD

Session XIII: Uveitis, Miscellaneous

Chair: Lee Jampol  
Moderator: Craig Greven
11:45 a.m.  Familial Aggregation Studies of the White Spot Syndrome
           Lee M. Jampol

11:54 a.m.  Visual Outcomes in Ocular Toxocariasis
           Craig M. Greven

12:03 p.m.  Combined Therapy of Systemic Steroids with Photodynamic Treatment: A Novel Strategy for
           the Management of Idiopathic Choroidal Neovascularization
           Alfonso Giovannini

12:21 p.m.  End of Session and Meeting